MRG003 with or without putrelimab for salivary gland cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug combination (MRG003 with or without putrelimab) for people with advanced salivary gland cancer that has EGFR protein. It aims to see if the treatment is safe and helps shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have recurrent or metastatic salivary gland cancer that cannot be surgically removed.
- Your tumor tests positive for a protein called EGFR.
- You have at least one tumor that can be measured on a CT scan.
- You are in relatively good health, with a performance status of 0 or 1 (able to carry out daily activities).
- You have not had other cancers in the last 5 years (except for certain skin or cervical cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs together: MRG003 (a targeted therapy that delivers chemo directly to EGFR-positive cancer cells) and pucotenlimab (an immunotherapy that helps your immune system attack the cancer). It is for people with a rare and aggressive thyroid cancer (ATC or PDTC) whose tumors have the EGFR protein and have grown despite previous treatment.
This study tests a new drug called MRG003 against two other treatments (cetuximab or methotrexate) for people with a type of head and neck cancer that has come back or spread and has not responded to standard treatments. The goal is to see if the new drug can better control the cancer and improve outcomes.
This trial tests a combination of two targeted drugs for advanced salivary gland cancer that has spread or cannot be removed with surgery. The drugs may block hormones and slow cancer growth, potentially helping people whose tumors have specific markers.
This trial tests a drug called MRG003 for people with certain advanced cancers that have a specific protein, EGFR. The drug targets the cancer cells that have this protein, which may help stop the cancer from growing.
This trial tests a personalized treatment approach for recurrent or metastatic salivary gland cancer. It uses special tests on your tumor to find the best targeted therapy for your specific cancer type.
This trial tests a new drug, MRG006A, for people with advanced solid tumors, especially liver cancer. It aims to see if the drug is safe and effective by targeting a protein called GPC3 found on some cancer cells.
Hear when a new Salivary Gland Carcinomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.